| Recruiting | Prospective Data Collection Initiative on Thoracic Malignancies NCT06996249 | Dutch Society of Physicians for Pulmonology and Tuberculosis | — |
| Recruiting | ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC NCT06426511 | Sun Yat-sen University | Phase 2 |
| Unknown | Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan NCT06293833 | University Hospital, Antwerp | N/A |
| Withdrawn | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer NCT06555263 | Sutro Biopharma, Inc. | Phase 2 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Ca NCT06530719 | Jin Ying | Phase 2 |
| Not Yet Recruiting | High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases NCT06319950 | Taizhou Hospital | Phase 2 |
| Unknown | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Prolifera NCT06231680 | Henan Cancer Hospital | Phase 2 |
| Terminated | Induction Chemo-Nivo in Unresectable Stage III NSCLC NCT06003075 | Ralph G Zinner | Phase 2 |
| Recruiting | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy NCT06667154 | Aline Fusco Fares, MD | Phase 2 |
| Unknown | Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management NCT06060964 | University of South Carolina | EARLY_Phase 1 |
| Recruiting | Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refracto NCT04691817 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| Enrolling By Invitation | Use of the ADL-Glittre Test in the Pre and Postoperative Period of Patients With Lung Cancer NCT05863013 | Centro Universitário Augusto Motta | N/A |
| Recruiting | Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Ca NCT05384873 | Fondazione IRCCS Policlinico San Matteo di Pavia | N/A |
| Terminated | Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced NCT05860296 | SignalChem Lifesciences Corporation | Phase 1 / Phase 2 |
| Active Not Recruiting | Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients NCT05415358 | Wake Forest University Health Sciences | — |
| Unknown | Prediction Model of ICIs Combined With Chemotherapy in Advanced NSCLC NCT05725915 | Beijing Red Clove Public Welfare Development Center | — |
| Recruiting | I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy NCT05537922 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Terminated | Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) NCT04638582 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2 |
| Unknown | Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After Lobectomy NCT05472350 | Jianxing He | N/A |
| Recruiting | A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatm NCT05085028 | Imperial College London | Phase 3 |
| Completed | Breathe Easier II: A Dyad-based Multiple Behavior Intervention NCT05956782 | University of South Carolina | N/A |
| Withdrawn | Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System NCT06722885 | Universitair Ziekenhuis Brussel | — |
| Completed | Effect of Exercise Training in Lung Cancer NCT05158530 | Riphah International University | N/A |
| Recruiting | Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay) NCT04611867 | Inna Chen, MD | N/A |
| Completed | Pulmonary Function After Arterial Sleeve Lobectomy NCT04981938 | Centre Hospitalier Régional Universitaire Montpellier | — |
| Terminated | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Sele NCT05061940 | Repertoire Immune Medicines | — |
| Completed | Trial of NanoPac Intratumoral Injection in Lung Cancer NCT04314895 | NanOlogy, LLC | Phase 2 |
| Completed | [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients NCT04678440 | University of California, Davis | EARLY_Phase 1 |
| Recruiting | Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer P NCT04222335 | University Hospital, Toulouse | N/A |
| Completed | Cios Mobile 3D Spin for Robotic Bronchoscopy NCT04740047 | Mayo Clinic | — |
| Completed | A Radiomic Model for Risk of Local Recurrence and DFS for T3 and T4 Non-small Cell Lung Cancer NCT06405815 | Jinling Hospital, China | — |
| Unknown | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity NCT04631731 | Western Sydney Local Health District | Phase 1 / Phase 2 |
| Unknown | Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Tr NCT04440800 | Royal Marsden NHS Foundation Trust | — |
| Recruiting | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients NCT04566432 | Geneplus-Beijing Co. Ltd. | — |
| Recruiting | A Multicenter Cancer Biospecimen Collection Study NCT04510129 | Cofactor Genomics, Inc. | — |
| Unknown | Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC NCT04028778 | Sun Yat-sen University | Phase 3 |
| Unknown | X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases NCT04415320 | Betta Pharmaceuticals Co., Ltd. | Phase 2 |
| Completed | Move For Surgery - A Novel Preconditioning Program NCT03689634 | St. Joseph's Healthcare Hamilton | Phase 3 |
| Active Not Recruiting | Palliative Thoracic ImmunoRT NCT03705806 | University Health Network, Toronto | — |
| Terminated | Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA NCT03499678 | HKGepitherapeutics | — |
| Active Not Recruiting | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer NCT03377023 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection NCT03704870 | University Health Network, Toronto | Phase 2 |
| Completed | Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer NCT03088930 | University of Colorado, Denver | Phase 2 |
| Completed | Move for Surgery (MFS): Evaluating the Use of Wearable Technology for Preconditioning Before Thoracic Surgery NCT03902834 | St. Joseph's Healthcare Hamilton | N/A |
| Unknown | Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Track NCT03322072 | CancerCare Manitoba | N/A |
| Completed | The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell C NCT04634630 | Beatrice Aramini | — |
| Completed | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. NCT03245736 | Seagen Inc. | Phase 2 |
| Unknown | Folate One-carbon Malnutrition as the Metabostemness Risk Factor of Malignancy Tumor Development of NSCLC Pati NCT03504098 | National Taiwan University Hospital | — |
| Completed | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China NCT03059641 | Geneplus-Beijing Co. Ltd. | — |
| Unknown | Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Muta NCT03008109 | Zaiwen Fan | Phase 3 |
| Completed | Effect of Qigong on the Symptom Clusters of Dyspnea, Fatigue, and Anxiety. NCT02977845 | Nam Dinh University of Nursing | N/A |
| Terminated | Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC NCT02991651 | Io Therapeutics | Phase 1 |
| Unknown | A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients NCT04237805 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 / Phase 2 |
| Unknown | Plasmodium Immunotherapy for Lung Cancer NCT02786589 | State Key Laboratory of Respiratory Disease | Phase 1 / Phase 2 |
| Completed | FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer NCT02995889 | Rigshospitalet, Denmark | N/A |